Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386049062> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4386049062 endingPage "e1004207" @default.
- W4386049062 startingPage "e1004207" @default.
- W4386049062 abstract "Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Inflammatory adverse events (iAEs) such as cytokine release syndrome (CRS) and neurotoxicity (NT) are common in patients with multiple myeloma (MM) treated with CAR T cell therapies such as ide-cel; CRS and NT observed with ide-cel are generally low grade and manageable with tocilizumab and corticosteroids. Identifying iAE risk with sensitivity and specificity is challenging, suggesting multifactorial etiology and limitations evaluating dynamic processes at specific timepoints. Macrophage activation syndrome (MAS; per Common Terminology Criteria for Adverse Events) has a specific molecular profile representing a homogeneous subgroup within CRS, tending to be more severe/refractory to front-line management. Aims: Using longitudinal data on post-infusion soluble factors, we aimed to develop a candidate post-infusion inflammatory risk score based on MAS molecular signature and determine associations with baseline characteristics in patients with MM. Methods: Statistical learning tools were applied to the longitudinal profile of 34 factors measured over 28 days after ide-cel infusion in 291 patients from KarMMa (NCT03361748) and KarMMa-2 (NCT03601078) to extract features describing the profiles. Unsupervised machine learning-based clustering was applied to these features and enrichment for MAS cases within each cluster was assessed. A metric describing membership in a cluster of interest was used as a candidate post-infusion inflammatory risk score for further correlative analyses. Results: Patients with MAS had cytokine profiles consistent with high levels of pro-inflammatory signaling across multiple inflammatory cell types. Cytokine profiles of MAS were qualitatively similar to those of CRS/NT; however, unsupervised clustering showed a distinct group of patients with MAS. A metric of similarity to the MAS-enriched cluster was defined as a candidate post-infusion inflammatory risk score, posited to identify patients more likely to have more severe/refractory iAEs. This inflammatory risk score positively correlated with CRS and NT grades and frequency of tocilizumab usage (Kruskal–Wallis test; all P < 0.001). A prototype predictive model based on baseline patient and clinical characteristics strongly correlated with post-infusion inflammatory risk score (Pearson; ρ= 0.88). Low blood counts, higher tumor burden, and elevated levels of inflammatory markers on the day of ide-cel infusion were associated with a higher inflammatory risk score. Summary/Conclusion: A molecular profile of severe/refractory iAEs was preliminarily identified in ide-cel-treated patients with MM. This profile enabled derivation of a candidate post-infusion inflammatory risk score and a prototype predictive model of this risk score based on patient baseline characteristics was developed. These results may help identify patients at risk for severe/refractory iAEs, who may be potential candidates for closer monitoring or novel interventions, and warrant further study. Keywords: Cytokine release syndrome, Risk factor, CAR-T, Multiple myeloma" @default.
- W4386049062 created "2023-08-23" @default.
- W4386049062 creator A5000717195 @default.
- W4386049062 creator A5002278734 @default.
- W4386049062 creator A5008762690 @default.
- W4386049062 creator A5031176423 @default.
- W4386049062 creator A5033935955 @default.
- W4386049062 creator A5034422841 @default.
- W4386049062 creator A5036677725 @default.
- W4386049062 creator A5069536069 @default.
- W4386049062 creator A5069553021 @default.
- W4386049062 creator A5091661800 @default.
- W4386049062 date "2023-08-01" @default.
- W4386049062 modified "2023-09-23" @default.
- W4386049062 title "P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS" @default.
- W4386049062 doi "https://doi.org/10.1097/01.hs9.0000970140.10042.07" @default.
- W4386049062 hasPublicationYear "2023" @default.
- W4386049062 type Work @default.
- W4386049062 citedByCount "0" @default.
- W4386049062 crossrefType "journal-article" @default.
- W4386049062 hasAuthorship W4386049062A5000717195 @default.
- W4386049062 hasAuthorship W4386049062A5002278734 @default.
- W4386049062 hasAuthorship W4386049062A5008762690 @default.
- W4386049062 hasAuthorship W4386049062A5031176423 @default.
- W4386049062 hasAuthorship W4386049062A5033935955 @default.
- W4386049062 hasAuthorship W4386049062A5034422841 @default.
- W4386049062 hasAuthorship W4386049062A5036677725 @default.
- W4386049062 hasAuthorship W4386049062A5069536069 @default.
- W4386049062 hasAuthorship W4386049062A5069553021 @default.
- W4386049062 hasAuthorship W4386049062A5091661800 @default.
- W4386049062 hasBestOaLocation W43860490621 @default.
- W4386049062 hasConcept C126322002 @default.
- W4386049062 hasConcept C143998085 @default.
- W4386049062 hasConcept C197934379 @default.
- W4386049062 hasConcept C203014093 @default.
- W4386049062 hasConcept C2776364478 @default.
- W4386049062 hasConcept C2777178219 @default.
- W4386049062 hasConcept C2777793932 @default.
- W4386049062 hasConcept C2778690821 @default.
- W4386049062 hasConcept C2779134260 @default.
- W4386049062 hasConcept C2780850621 @default.
- W4386049062 hasConcept C3008058167 @default.
- W4386049062 hasConcept C524204448 @default.
- W4386049062 hasConcept C60644358 @default.
- W4386049062 hasConcept C71924100 @default.
- W4386049062 hasConcept C86803240 @default.
- W4386049062 hasConceptScore W4386049062C126322002 @default.
- W4386049062 hasConceptScore W4386049062C143998085 @default.
- W4386049062 hasConceptScore W4386049062C197934379 @default.
- W4386049062 hasConceptScore W4386049062C203014093 @default.
- W4386049062 hasConceptScore W4386049062C2776364478 @default.
- W4386049062 hasConceptScore W4386049062C2777178219 @default.
- W4386049062 hasConceptScore W4386049062C2777793932 @default.
- W4386049062 hasConceptScore W4386049062C2778690821 @default.
- W4386049062 hasConceptScore W4386049062C2779134260 @default.
- W4386049062 hasConceptScore W4386049062C2780850621 @default.
- W4386049062 hasConceptScore W4386049062C3008058167 @default.
- W4386049062 hasConceptScore W4386049062C524204448 @default.
- W4386049062 hasConceptScore W4386049062C60644358 @default.
- W4386049062 hasConceptScore W4386049062C71924100 @default.
- W4386049062 hasConceptScore W4386049062C86803240 @default.
- W4386049062 hasIssue "S3" @default.
- W4386049062 hasLocation W43860490621 @default.
- W4386049062 hasOpenAccess W4386049062 @default.
- W4386049062 hasPrimaryLocation W43860490621 @default.
- W4386049062 hasRelatedWork W2151082410 @default.
- W4386049062 hasRelatedWork W2318150798 @default.
- W4386049062 hasRelatedWork W2379764382 @default.
- W4386049062 hasRelatedWork W2594853348 @default.
- W4386049062 hasRelatedWork W2980542859 @default.
- W4386049062 hasRelatedWork W3026277345 @default.
- W4386049062 hasRelatedWork W3092879025 @default.
- W4386049062 hasRelatedWork W3201811998 @default.
- W4386049062 hasRelatedWork W4285795734 @default.
- W4386049062 hasRelatedWork W3214604417 @default.
- W4386049062 hasVolume "7" @default.
- W4386049062 isParatext "false" @default.
- W4386049062 isRetracted "false" @default.
- W4386049062 workType "article" @default.